Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Claudia Omarini
Observed names:
C Omarini,
C. Omarini,
Omarini, C.,
Omarini, Claudia
Institutions:
University of Modena and Reggio Emilia,
Azienda Ospedaliero-Universitaria di Modena
Observed institutions:
University of Modena and Reggio Emilia,
Royal Marsden NHS Foundation Trust,
Italian Oncology Group of Clinical Research,
Azienda Ospedaliero-Universitaria di Modena,
Royal Marsden Hospital,
Instituto Nazionale Tumori Regina Elena
show all 6
ORCID:
0000-0002-2906-7896
Observed ORCID:
0000-0002-2906-7896
OpenAlex ID:
A5041223140
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
2013
·
V. Guarneri
, M.V. Dieci
, et al.
·
Annals of Oncology
·
140
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
2023
·
Krisida Cerma
, Federico Piacentini
, et al.
·
Biomedicines
·
115
PDF
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era
2021
·
A. Toss
, C. Isca
, et al.
·
ESMO Open
·
105
PDF
Immune characterization of breast cancer metastases: prognostic implications
2018
·
Maria Vittoria Dieci
, Vassilena Tsvetkova
, et al.
·
Breast Cancer Research
·
91
PDF
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
2018
·
Claudia Omarini
, Giorgia Guaitoli
, et al.
·
Cancer Management and Research
·
80
PDF
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience
2017
·
Patrizia Vici
, Laura Pizzuti
, et al.
·
Oncotarget
·
69
PDF
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients
2016
·
C. Omarini
, G. Guaitoli
, et al.
·
European Journal of Surgical Oncology
·
66
Pneumonitis and pulmonary fibrosis associated with breast cancer treatments
2014
·
Claudia Omarini
, Eirini Thanopoulou
, et al.
·
Breast Cancer Research and Treatment
·
65
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
2021
·
M. Del Re
, C. Omarini
, et al.
·
ESMO Open
·
63
PDF
The Role of Exosomes in Breast Cancer Diagnosis
2021
·
Claudia Piombino
, Ilenia Mastrolia
, et al.
·
Biomedicines
·
51
PDF
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!
2020
·
Claudia Omarini
, Michela Maur
, et al.
·
European Journal of Cancer
·
43
PDF
A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study
2018
·
Teresa Gamucci
, Laura Pizzuti
, et al.
·
Cancer Biology & Therapy
·
42
PDF
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer
2019
·
Sandro Pignata
, Giovanni Scambia
, et al.
·
Gynecologic Oncology
·
35
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
2019
·
Claudia Omarini
, Patrizia Palumbo
, et al.
·
Cancer Management and Research
·
32
PDF
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients
2018
·
Claudia Omarini
, Stefania Bettelli
, et al.
·
Cancer Biology & Therapy
·
30
PDF
Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib
2022
·
Marzia Del Re
, Stefania Crucitta
, et al.
·
The Breast
·
23
PDF
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
2022
·
Angela Toss
, Marta Venturelli
, et al.
·
Frontiers in Oncology
·
22
Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist
2022
·
Fabio Canino
, Claudia Omarini
, et al.
·
Clinical Breast Cancer
·
22
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
2022
·
A. Viansone
, B. Pellegrino
, et al.
·
The Breast
·
20
PDF
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications
2018
·
Angela Toss
, Federico Piacentini
, et al.
·
Oncotarget
·
18
PDF
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis
2019
·
Angela Toss
, Marta Venturelli
, et al.
·
Clinical Breast Cancer
·
17
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes
2025
·
Claudia Omarini
, Virginia Catani
, et al.
·
Biomarker Research
·
15
PDF
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis
2012
·
Maria Vittoria Dieci
, Elena Barbieri
, et al.
·
Journal of Clinical Pathology
·
15
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients
2024
·
Elena Giordani
, Matteo Allegretti
, et al.
·
Journal of Experimental & Clinical Cancer Research
·
14
PDF
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study
2024
·
Fabio Canino
, Monica Barbolini
, et al.
·
BMC Cancer
·
13
Show more works
View as search
Works count:
136
Citation count:
1,428
H-index:
19
I10-index:
35
Year
Topic
Type